All In Biotech

Drug Trial Radar · NCT03447314

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

54

Actual

Start

Mar 26, 2018

Primary completion

Jul 1, 2020

Study completion Mar 11, 2022

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Feb 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GSK1795091 is being developed for administration in combination with other immune system modulators for the treatment of cancers. The study will be conducted in two parts. In Part 1, dose escalation will be performed to identify combination dose levels comprising GSK1795091 with either 24 milligrams (mg) GSK3174998 (Part 1a), 80 mg GSK3359609 (Part 1b), or 200 mg pembrolizumab (Part 1c). One dose level of GSK3174998, GSK3359609, or pembrolizumab with up to 5 dose levels of GSK1795091 are planned for evaluation. In Part 2 (dose-expansion), subjects will receive a single dose level of GSK1795091 as identified based on data from Part 1, in combination with either GSK3174998, GSK3359609, or pembrolizumab.

Conditions

  • Neoplasms

Interventions

  • GSK1795091Drug

    GSK1795091 will be available as solution for injection

  • GSK3174998Drug

    GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.

  • GSK3359609Drug

    GSK3359609 will be available as solution for infusion.

  • PembrolizumabDrug

    Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (STEAEs)Time frame: Up to 27 months
  2. Part 2: Number of Participants With TEAEs and STEAEsTime frame: Up to 27 months
  3. Part 1: Number of Participants With Dose-limiting Toxicity (DLT)Time frame: 42 days
  4. Part 1: Number of Participants With TEAEs Leading to DiscontinuationTime frame: Up to 2 years
  5. Part 2: Number of Participants With TEAEs Leading to DiscontinuationTime frame: Up to 2 years
  6. Part 1: Number of Participants With TEAEs Leading to Dose Reductions or Dose DelaysTime frame: Up to 2 years
  7. Part 2: Number of Participants With TEAEs Leading to Dose Reductions or Dose DelaysTime frame: Up to 2 years
  8. Part 1: Number of Participants With Change From Baseline in Hematology Parameters With Respect to the Normal RangeTime frame: Baseline (Day 1: Pre-dose) and up to 2 years
  9. Part 2: Number of Participants With Change From Baseline in Hematology Parameters With Respect to the Normal RangeTime frame: Baseline (Day 1: Pre-dose) and up to 2 years
  10. Part 1: Number of Participants With Change From Baseline in Chemistry Parameters With Respect to the Normal RangeTime frame: Baseline (Day 1: Pre-dose) and up to 2 years
  11. Part 2: Number of Participants With Change From Baseline in Chemistry Parameters With Respect to the Normal RangeTime frame: Baseline (Day 1: Pre-dose) and up to 2 years
  12. Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range CriteriaTime frame: Up to 2 years
  13. Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range CriteriaTime frame: Up to 2 years
  14. Part 1: Number of Participants With Increase From Baseline in Vital Signs According to Markedly Abnormal CriteriaTime frame: Up to 2 years
  15. Part 2: Number of Participants With Vital Signs Any Increases From Baseline According to Markedly Abnormal CriteriaTime frame: Up to 2 years
  16. Part 1: Number of Participants With Any Decrease From Baseline in Vital Sign According to Markedly Abnormal CriteriaTime frame: Up to 2 years
  17. Part 2: Number of Participants With Vital Signs Any Decreases From Baseline According to Markedly Abnormal CriteriaTime frame: Up to 2 years
  18. Part 1: Number of Participants With Any Increase From Baseline in Corrected QT Interval Using Fredericia's Formula (QTcF) According to Markedly Abnormal CriteriaTime frame: Up to 2 years
  19. Part 2: Number of Participants With Any QTcF Interval Increases From Baseline According to Markedly Abnormal CriteriaTime frame: Up to 2 years

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Tacoma, Washington

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Amsterdam, Netherlands

  • GSK Investigational Site

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.